HemOnc Today


The following articles appeared in the print edition of HEMONC TODAY.

Table of Contents
Cover Story

Gene therapy represents ‘new paradigm’ for treatment of hematologic disorders


The year of living dangerously

Derek Raghavan, MD, PhD

FDA approvals

FDA approves Keytruda for first-line treatment of metastatic melanoma

FDA approves digestive enzyme cartridge for enteral tube feeding

FDA News

FDA grants orphan drug designation to GBT 440 for sickle cell disease

FDA grants Cellceutix rare pediatric disease designation for Kevetrin to treat retinoblastoma

FDA issues final guidance on blood donations from MSM

FDA issues safety alert for antifungal medication dosages, approves label revisions

FDA grants breakthrough therapy designation to BI 1482694 for NSCLC

In the Journals

Ablative therapies show promise for advanced pancreatic cancer

Swallowing disorders may warrant routine esophagoscopy examination in patients with HNSCC

USPSTF breast cancer screening recommendations remain unchanged despite controversy

Cediranib plus chemotherapy effective for cervical cancer

ACS: Cancer death rate declines 23% from all-time high

Institution Notes

University of Michigan Cancer Center names associate director

Society presents awards to MD Anderson professor

Association of Pediatric Hematology/Oncology Nurses presents awards

Cancer researcher to lead Einstein’s Belfer Institute

AACR honors professor with breast cancer research lectureship

Genomics expert joins Children’s Hospital of Philadelphia

Meeting News Coverage

Regular aspirin intake reduces risk for lethal prostate cancer

Breast-conserving therapy extends OS in early-stage breast cancer

Anastrozole, tamoxifen demonstrate similar efficacy, different safety profiles for DCIS

Recombinant Factor VIII products increase inhibitor development in severe hemophilia A

Hydroxyurea shows promise for stroke prevention in pediatric patients with sickle cell anemia

Early PET scans guide de-escalation of therapy for advanced Hodgkin’s lymphoma

Eltrombopag improves platelet counts, reduces fatigue for some patients with severe thrombocytopenia

Idelalisib combination reduces risk for progression, death in refractory CLL

Liquid biopsy could help guide prostate cancer treatment

Midostaurin confers OS, EFS benefits in FLT3-mutated AML

Interim PET scans predict relapse of non-bulky early-stage Hodgkin’s lymphoma

Pharmacology Consult

Biosimilars may expand drug access, reduce costs, but still much to learn

Jai N. Patel, PharmD